Dynavax Technologies (NASDAQ:DVAX) Hits New 12-Month Low at $10.02

Dynavax Technologies Co. (NASDAQ:DVAX)’s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $10.02 and last traded at $10.12, with a volume of 19777 shares trading hands. The stock had previously closed at $10.53.

Analyst Ratings Changes

Several equities analysts have recently commented on DVAX shares. HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a report on Wednesday. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.33.

Dynavax Technologies Price Performance

The company’s 50-day moving average price is $11.26 and its 200-day moving average price is $11.88. The company has a quick ratio of 14.10, a current ratio of 15.20 and a debt-to-equity ratio of 0.36. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of 167.50 and a beta of 1.28.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. During the same quarter last year, the firm posted $0.03 EPS. On average, equities research analysts forecast that Dynavax Technologies Co. will post 0.12 EPS for the current year.

Insider Activity

In related news, Director Francis Cano sold 3,615 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.93, for a total value of $43,126.95. Following the sale, the director now owns 36,905 shares of the company’s stock, valued at $440,276.65. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 2.98% of the company’s stock.

Hedge Funds Weigh In On Dynavax Technologies

Institutional investors and hedge funds have recently modified their holdings of the company. Duality Advisers LP purchased a new stake in Dynavax Technologies during the 1st quarter worth about $227,000. Natixis Advisors L.P. raised its position in shares of Dynavax Technologies by 10.5% during the 4th quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 1,804 shares in the last quarter. Executive Wealth Management LLC purchased a new stake in Dynavax Technologies during the fourth quarter worth approximately $280,000. Boston Partners acquired a new position in Dynavax Technologies in the first quarter valued at approximately $292,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Dynavax Technologies by 67.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock valued at $311,000 after purchasing an additional 10,143 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.